Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term?

1 week ago 6

Soumya Eswaran

Thu, December 18, 2025 astatine 8:27 AM CST 2 min read

Parnassus Investments, an concern absorption firm, released its “Parnassus Value Equity Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The money focuses connected owning a concentrated portfolio of U.S. large-cap stocks. For the 3rd 4th of 2025, the money reported a nett instrumentality of 7.46% outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the aforesaid period. During the quarter, the portfolio reduced its value successful the IT assemblage to summation holdings successful the Health Care sector. The fund’s apical 5 holdings are besides listed successful the letter, showing the firm’s main concern positions heading into 2025.

In its third-quarter 2025 capitalist letter, Parnassus Value Equity Fund highlighted stocks specified arsenic Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is simply a starring shaper of wellness attraction products. The one-month instrumentality of Abbott Laboratories (NYSE:ABT) was -1.09%, and its shares gained 10.93% of their worth implicit the past 52 weeks. On December 17, 2025, Abbott Laboratories (NYSE:ABT) banal closed astatine $126.71 per share, with a marketplace capitalization of $220.534 billion.

Parnassus Value Equity Fund stated the pursuing regarding Abbott Laboratories (NYSE:ABT) successful its 3rd 4th 2025 capitalist letter:

"Abbott Laboratories (NYSE:ABT) stands retired for its durable maturation imaginable driven by dependable request successful areas similar diabetes care, bosom wellness and electrophysiology, each supported by ongoing innovation and caller merchandise launches. We besides judge Abbott’s diversified concern model, planetary scope and enactment positions successful cardinal markets tin supply resilient returns for semipermanent investors."

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Abbott Laboratories (NYSE:ABT) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge money portfolios held Abbott Laboratories (NYSE:ABT) astatine the extremity of the 3rd quarter, which was 69 successful the erstwhile quarter. While we admit the imaginable of Abbott Laboratories (NYSE:ABT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the database of champion dilatory maturation stocks to put in. Abbott Laboratories (NYSE:ABT) detracted from Carillon Eagle Growth & Income Fund's show successful Q3 2025 owed to anemic quarterly net and reduced fiscal guidance. In addition, delight cheque retired our hedge money capitalist letters Q3 2025 page for much capitalist letters from hedge funds and different starring investors.